Breast cancer trials recruiting in North Carolina

All Breast cancer trials nationally

Cities in North Carolina

Recruiting trials in North Carolina

• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  NCT07060807 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Winston-Salem
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
  NCT04641247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Wilson
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Huntersville
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Wilson
• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Asheville, Durham, Morrisville
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
  NCT06790693 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Durham, Winston-Salem
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
  NCT05646862 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Winston-Salem
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
  NCT04802759 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · North Carolina: Charlotte
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
  NCT07488676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female) · North Carolina: Charlotte, Durham, Greensboro, Raleigh
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Huntersville
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham, Fayetteville, Greensboro
• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
  NCT06099769 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · North Carolina: Chapel Hill
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
  NCT07213791 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
  NCT05877599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Winston-Salem
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  NCT06312176 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  NCT06841354 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Garner
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Asheville, Cary, Chapel Hill, Wilson
• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
  NCT05503797 · Phase: Phase 2 · Ages: 8 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Raleigh
• A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
  NCT07100106 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Winston-Salem
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
  NCT05894239 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Cary, Chapel Hill, Clinton, Garner
• An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
  NCT07357597 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Greensboro, Wilson
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
  NCT07360314 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Huntersville
• Asciminib in HER2+ Breast Cancer Brain Metastases
  NCT07136428 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · North Carolina: Durham
• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
  NCT06418204 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Albemarle, Asheboro, Burlington, Charlotte
• Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
  NCT07264790 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · North Carolina: Durham
• Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
  NCT07140172 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
  NCT07492641 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Hendersonville, Wilson
• BREAST Choice Decision Tool R21 - AIM2
  NCT06817226 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
  NCT05029999 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · North Carolina: Asheville, Cary, Clinton, Clyde
• Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
  NCT05472792 · Phase: Phase 2 · Ages: 65 Years and older · Sex: Female · North Carolina: Chapel Hill
• Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
  NCT05625659 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 74 Years · Sex: Female · North Carolina: Greenville
• Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
  NCT01000883 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
  NCT06176261 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
  NCT06075953 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · North Carolina: Durham, Winston-Salem
• De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
  NCT04852887 · Phase: Phase 3 · Ages: 50 Years to 70 Years · Sex: All (male and female) · North Carolina: Albemarle, Asheville, Charlotte, Clemmons
• Dissemination of BREASTChoice AIM1-B
  NCT07396766 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Distance-Based Exercise to Preserve Function and Prevent Disability
  NCT07059884 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Kernersville, Mount Airy, Winston-Salem
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · North Carolina: Albemarle, Asheboro, Burlington, Charlotte
• ETHAN - ET for Male BC
  NCT05501704 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · North Carolina: Chapel Hill
• EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
  NCT06401421 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Pinehurst, Rocky Mount, Winston-Salem
• Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
  NCT04373564 · Phase: Phase 4 · Ages: 18 Years to 64 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
  NCT06848348 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• Engage Psychosocial Intervention for Cancer Symptoms
  NCT06555588 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female · North Carolina: Albemarle, Asheboro, Burlington, Cary
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
  NCT05696626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
  NCT05440929 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · North Carolina: Chapel Hill
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
  NCT07340541 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
  NCT07313306 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
  NCT03769415 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 99 Years · Sex: All (male and female) · North Carolina: Chapel Hill, Raleigh
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• Identifying Patterns in the Breath of Individuals With Breast Cancer
  NCT06512350 · Phase: Not specified · Ages: 40 Years to 74 Years · Sex: Female · North Carolina: Durham
• Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
  NCT04677816 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• Improving Exercise Capacity With a Tailored Physical Activity Intervention
  NCT05595577 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · North Carolina: Winston-Salem
• Increasing Germline Genetic Testing for Patients With Cancer
  NCT07307664 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · North Carolina: Durham, Salisbury
• Integrated Cancer Repository for Cancer Research
  NCT02012699 · Phase: Not specified · Ages: 19 Years to 110 Years · Sex: All (male and female) · North Carolina: Fayetteville
• Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
  NCT07214610 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 74 Years · Sex: Female · North Carolina: Chapel Hill
• Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
  NCT05557877 · Phase: Phase 2 · Ages: 18 Years to 45 Years · Sex: Female · North Carolina: Chapel Hill
• Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
  NCT06727773 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · North Carolina: Chapel Hill
• Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
  NCT07025785 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
  NCT02945579 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years and older · Sex: Female · North Carolina: Charlotte
• Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
  NCT07389967 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · North Carolina: Chapel Hill
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Durham
• Optimizing Surgical Decisions in Young Adults With Breast Cancer
  NCT06275126 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 44 Years · Sex: Female · North Carolina: Durham
• PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
  NCT06610539 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
  NCT07069595 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
  NCT06896162 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial
  NCT07474090 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · North Carolina: Winston-Salem
• Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
  NCT06993844 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Huntersville
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
  NCT05827081 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · North Carolina: Durham, Greensboro
• Planning Grant for TOPS for Breast Cancer Survivors
  NCT06658912 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years to 90 Years · Sex: Female · North Carolina: Durham
• Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
  NCT07276880 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
  NCT06855654 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
  NCT02422641 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
  NCT06551116 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
  NCT07173751 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
  NCT05974150 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill, Durham
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
  NCT03418961 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Clinton, Goldsboro, Jacksonville
• S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
  NCT03723928 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Clinton, Gastonia, Goldsboro, Jacksonville
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · North Carolina: Chapel Hill, Winston-Salem
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
  NCT04468061 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Fayetteville
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Cary, Chapel Hill, Charlotte, Clemmons
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
  NCT05929768 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Asheboro, Asheville, Burlington, Chapel Hill
• Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
  NCT07214532 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte